Non Profit Investment

We are a nonprofit investing in revolutionary human

genetic research to advance cures

Health For

Healthy Food

Get Free

Pure Education

Get Free

Medical Facilities

WHO WE ARE

A cornerstone for human genetic research and discovery

Our primary objective is to fight against cancer, and Alzheimer's, helping charities mostly casualties of war, and also making a difference in the life of the less privileged.

The Scott R. MacKenzie Foundation funds leading-edge human genetic research (DNA, RNA, protein) to advance cures for cancer, lung disease, diabetes, and heart disease.

OUR PROGRAM

Funding is available for tax-exempt United States based organizations

We fund innovative, scientific researchers and centers of excellence that work collaboratively in sentinel genome sequencing and advanced research to develop new treatment pathways for cancer, lung disease, diabetes, and heart disease.

YIELD GIVING

yield: (verb) 1. to increase 2. to give up control

Established by MacKenzie Scott to share a financial fortune created through the effort of countless people, Yield is named after a belief in adding value by giving up control. To date, our network of staff and advisors has yielded over $14,000,000,000 to 1,600+ non-profit teams to use as they see fit for the benefit of others.

Information has been shared publicly in this series of essays.

Funding Opportunities

What Do We Fund?

Funding is available for tax-exempt United States based organizations and qualified collaborative partners on a mission to find a cure for:

00+

Number of grants

$00M

Direct grant recipient support

$00M

Current average annual funding

Grant Application

Jacksonville’s Scott R. MacKenzie
Foundation offers grants for
genetic research

From Our Blog

Latest News

MacKenzie Scott donates $640 million to 361 nonprofits

Scott, a co-founder of Amazon and ex-wife of Jeff Bezos, has been periodically updating the public on her donations as part of her vow to give half her wealth to charity.

Scott R. MacKenzie Foundation awards $350,000 in support of two-year clinical trial

Diana Azzam, a researcher in the Robert Stempel College of Public Health & Social Work, will collaborate with Cleveland Clinic Florida on a study to find new treatment options for cancer patients.

Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes

Francesco Franchi, MD, Fabiana Rollini, MD, Jose Rivas, MD, Andrea Rivas, MD, Malhar Agarwal, MD, Maryuri Briceno, MD, Mustafa Wali, MD, Ahmed Nawaz, MD, Gabriel Silva, MD, Zubair Shaikh, MD, Naji Maailiki, MD, Latonya Been, AAS, Andres M. Pineda, MD